Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity

Carol M Richman, C. A. Slapak, B. Toh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Interferons (IFN) have clinical efficacy in certain hematologic malignancies. Combining IFN with conventional cytotoxic agents has been proposed as a means of improving therapy for diseases such as chronic myelogenous leukemia (CML). In this study, we examined the effect of recombinant interferons alone and in combination with Ara-C on normal and leukemic human hematopoietic progenitor cells (CFU-GM) in vitro. Mononuclear cells from normal bone marrow, peripheral blood of patients with CML, or the acute nonlymphocytic leukemia cell line HL-60 were incubated with α-, β-, or γ-IFN (0-1,000 units/ml) followed by the addition of Ara-C. The survival of normal CFU-GM was significantly increased if cells were treated with IFN 1 h before 3 h of Ara-C exposure. Similar IFN pretreatment of CML and HL-60 progenitors failed to protect leukemic CFU-GM from Ara-C-induced toxicity. This selective protection of normal CFU-GM may have clinical application.

Original languageEnglish (US)
Pages (from-to)570-575
Number of pages6
JournalJournal of Biological Response Modifiers
Volume9
Issue number6
StatePublished - 1990
Externally publishedYes

Fingerprint

Cytarabine
Granulocytes
Interferons
Granulocyte-Macrophage Progenitor Cells
Macrophages
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytotoxins
Hematologic Neoplasms
Hematopoietic Stem Cells
Acute Myeloid Leukemia
Bone Marrow Cells
Cell Line

Keywords

  • Ara-C
  • Chemotherapy
  • Granulocyte/macrophage colony-forming cells
  • Interferon
  • Leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity. / Richman, Carol M; Slapak, C. A.; Toh, B.

In: Journal of Biological Response Modifiers, Vol. 9, No. 6, 1990, p. 570-575.

Research output: Contribution to journalArticle

@article{48d536745ccd469fa03daedfe5d1969d,
title = "Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity",
abstract = "Interferons (IFN) have clinical efficacy in certain hematologic malignancies. Combining IFN with conventional cytotoxic agents has been proposed as a means of improving therapy for diseases such as chronic myelogenous leukemia (CML). In this study, we examined the effect of recombinant interferons alone and in combination with Ara-C on normal and leukemic human hematopoietic progenitor cells (CFU-GM) in vitro. Mononuclear cells from normal bone marrow, peripheral blood of patients with CML, or the acute nonlymphocytic leukemia cell line HL-60 were incubated with α-, β-, or γ-IFN (0-1,000 units/ml) followed by the addition of Ara-C. The survival of normal CFU-GM was significantly increased if cells were treated with IFN 1 h before 3 h of Ara-C exposure. Similar IFN pretreatment of CML and HL-60 progenitors failed to protect leukemic CFU-GM from Ara-C-induced toxicity. This selective protection of normal CFU-GM may have clinical application.",
keywords = "Ara-C, Chemotherapy, Granulocyte/macrophage colony-forming cells, Interferon, Leukemia",
author = "Richman, {Carol M} and Slapak, {C. A.} and B. Toh",
year = "1990",
language = "English (US)",
volume = "9",
pages = "570--575",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity

AU - Richman, Carol M

AU - Slapak, C. A.

AU - Toh, B.

PY - 1990

Y1 - 1990

N2 - Interferons (IFN) have clinical efficacy in certain hematologic malignancies. Combining IFN with conventional cytotoxic agents has been proposed as a means of improving therapy for diseases such as chronic myelogenous leukemia (CML). In this study, we examined the effect of recombinant interferons alone and in combination with Ara-C on normal and leukemic human hematopoietic progenitor cells (CFU-GM) in vitro. Mononuclear cells from normal bone marrow, peripheral blood of patients with CML, or the acute nonlymphocytic leukemia cell line HL-60 were incubated with α-, β-, or γ-IFN (0-1,000 units/ml) followed by the addition of Ara-C. The survival of normal CFU-GM was significantly increased if cells were treated with IFN 1 h before 3 h of Ara-C exposure. Similar IFN pretreatment of CML and HL-60 progenitors failed to protect leukemic CFU-GM from Ara-C-induced toxicity. This selective protection of normal CFU-GM may have clinical application.

AB - Interferons (IFN) have clinical efficacy in certain hematologic malignancies. Combining IFN with conventional cytotoxic agents has been proposed as a means of improving therapy for diseases such as chronic myelogenous leukemia (CML). In this study, we examined the effect of recombinant interferons alone and in combination with Ara-C on normal and leukemic human hematopoietic progenitor cells (CFU-GM) in vitro. Mononuclear cells from normal bone marrow, peripheral blood of patients with CML, or the acute nonlymphocytic leukemia cell line HL-60 were incubated with α-, β-, or γ-IFN (0-1,000 units/ml) followed by the addition of Ara-C. The survival of normal CFU-GM was significantly increased if cells were treated with IFN 1 h before 3 h of Ara-C exposure. Similar IFN pretreatment of CML and HL-60 progenitors failed to protect leukemic CFU-GM from Ara-C-induced toxicity. This selective protection of normal CFU-GM may have clinical application.

KW - Ara-C

KW - Chemotherapy

KW - Granulocyte/macrophage colony-forming cells

KW - Interferon

KW - Leukemia

UR - http://www.scopus.com/inward/record.url?scp=0025647121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025647121&partnerID=8YFLogxK

M3 - Article

C2 - 1705960

AN - SCOPUS:0025647121

VL - 9

SP - 570

EP - 575

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -